Lineage Cell Therapeutics, Inc.(LCTX)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Lineage Cell Therapeutics, Inc. (LCTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LCTX at 25.4/100 on a 32-signal composite quality model, placing it at rank #2,661 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (2.7) and free cash flow (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Lineage Cell Therapeutics, Inc. reports quarterly revenue of $1.1M, net income of $1.5M, free cash flow of $-7.4M. Top institutional holders of LCTX by reported 13-F value include BROADWOOD CAPITAL, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LCTX trades on the NYSE exchange and files with the SEC under CIK 876343. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LCTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lineage Cell Therapeutics, Inc. directly from SEC EDGAR.